Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is suggested as a risk factor for chronic kidney disease (CKD). The incidence of NAFLD is rising globally in parallel to the increasing incidences of obesity and type 2 diabetes. Diabetes remains the leading cause of CKD, but the co-existence of NAFLD, CKD, and type 2 diabetes is not well elucidated. Here, we evaluated the prevalence of NAFLD in patients with type 2 diabetes with and without CKD. Methods: This was a cross-sectional study including 50 patients with type 2 diabetes and CKD stages 3–5 (no dialysis), and 50 patients with type 2 diabetes without CKD. Liver fat content was estimated by proton magnetic resonance spectroscopy and magnetic resonance imaging proton density fat fraction. NAFLD was defined as liver fat fraction ≥5.6% according to guidelines. Results: Mean age was 72 ± 4.9 years in patients with CKD and 65.9 ± 7.8 years in patients without CKD ( p < 0.0001). Three out of four participants were men. BMI was 28.6 ± 3.5 kg/m<sup>2</sup> and 27 ± 4.0 kg/m<sup>2</sup> in patients with and without CKD, respectively ( p = 0.0087). NAFLD was identified in 22 (44%) patients with CKD and 19 (38%) patients without CKD ( p = 0.6845). Median (IQR) liver fat fraction was 4.7% (3.0–8.5) and 4.1% (2.9–7.7) in patients with and without CKD, respectively (difference in geometric means 5.3%, 95% CI −23; 45, p = 0.7463). Conclusion: These findings do not support any association between NAFLD and CKD (stages 3–5) in patients with type 2 diabetes.

Related collections

Most cited references 53

Record: found
Abstract: found
Article: not found

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Zobair Younossi, Aaron Koenig, Dinan Abdelatif … (2016)

Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver disease worldwide. We estimated the global prevalence, incidence, progression, and outcomes of NAFLD and nonalcoholic steatohepatitis (NASH). PubMed/MEDLINE were searched from 1989 to 2015 for terms involving epidemiology and progression of NAFLD. Exclusions included selected groups (studies that exclusively enrolled morbidly obese or diabetics or pediatric) and no data on alcohol consumption or other liver diseases. Incidence of hepatocellular carcinoma (HCC), cirrhosis, overall mortality, and liver-related mortality were determined. NASH required histological diagnosis. All studies were reviewed by three independent investigators. Analysis was stratified by region, diagnostic technique, biopsy indication, and study population. We used random-effects models to provide point estimates (95% confidence interval [CI]) of prevalence, incidence, mortality and incidence rate ratios, and metaregression with subgroup analysis to account for heterogeneity. Of 729 studies, 86 were included with a sample size of 8,515,431 from 22 countries. Global prevalence of NAFLD is 25.24% (95% CI: 22.10-28.65) with highest prevalence in the Middle East and South America and lowest in Africa. Metabolic comorbidities associated with NAFLD included obesity (51.34%; 95% CI: 41.38-61.20), type 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertension (39.34%; 95% CI: 33.15-45.88), and metabolic syndrome (42.54%; 95% CI: 30.06-56.05). Fibrosis progression proportion, and mean annual rate of progression in NASH were 40.76% (95% CI: 34.69-47.13) and 0.09 (95% CI: 0.06-0.12). HCC incidence among NAFLD patients was 0.44 per 1,000 person-years (range, 0.29-0.66). Liver-specific mortality and overall mortality among NAFLD and NASH were 0.77 per 1,000 (range, 0.33-1.77) and 11.77 per 1,000 person-years (range, 7.10-19.53) and 15.44 per 1,000 (range, 11.72-20.34) and 25.56 per 1,000 person-years (range, 6.29-103.80). Incidence risk ratios for liver-specific and overall mortality for NAFLD were 1.94 (range, 1.28-2.92) and 1.05 (range, 0.70-1.56).

0 comments Cited 3064 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.

K. Ogurtsova, J.D. da Rocha Fernandes, Y. Huang … (2017)

To produce current estimates of the national, regional and global impact of diabetes for 2015 and 2040.

0 comments Cited 1397 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Tadej Battelino, Thomas Danne, Richard M. Bergenstal … (2019)

Improvements in sensor accuracy, greater convenience and ease of use, and expanding reimbursement have led to growing adoption of continuous glucose monitoring (CGM). However, successful utilization of CGM technology in routine clinical practice remains relatively low. This may be due in part to the lack of clear and agreed-upon glycemic targets that both diabetes teams and people with diabetes can work toward. Although unified recommendations for use of key CGM metrics have been established in three separate peer-reviewed articles, formal adoption by diabetes professional organizations and guidance in the practical application of these metrics in clinical practice have been lacking. In February 2019, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address this issue. This article summarizes the ATTD consensus recommendations for relevant aspects of CGM data utilization and reporting among the various diabetes populations.

0 comments Cited 1002 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (publisher-id): NEF

Journal ID (nlm-ta): Nephron

Journal ID (doi): 10.1159/issn.1660-8151

Title: Nephron

Abbreviated Title: Nephron

Publisher: S. Karger AG

ISSN (Print): 1660-8151

ISSN (Electronic): 2235-3186

Publication date Subscription-year: 2023

Publication date (Print): June 2023

Publication date (Electronic): 11 January 2023

Volume: 147

Issue: 6

Pages: 317-328

Affiliations

[_a] _aDepartment of Nephrology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark

[_b] _bDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

[_c] _cCenter for Clinical Metabolic Research, Copenhagen University Hospital – Gentofte Hospital, Hellerup, Denmark

[_d] _dNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark

[_e] _eSteno Diabetes Center Copenhagen, Herlev, Denmark

[_f] _fDepartment of Endocrinology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark

[_g] _gDepartment of Immunology and Microbiology, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark

[_h] _hDanish Research Centre for Magnetic Resonance, Centre for Functional and Diagnostic Imaging and Research, Copenhagen University Hospital – Amager and Hvidovre, Copenhagen, Denmark

[_i] _iDepartment of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark

[_j] _jDepartment of Neurology, Copenhagen University Hospital – Bispebjerg and Frederiksberg, Copenhagen, Denmark

Author information

Filip Krag Knop https://orcid.org/0000-0002-2495-5034

Peter Rossing https://orcid.org/0000-0002-1531-4294

Niels Søndergaard Heinrich https://orcid.org/0000-0002-6786-807X

Vincent Oltman Boer https://orcid.org/0000-0001-6026-3134

Esben Thade Petersen https://orcid.org/0000-0001-7529-3432

Article

Publisher ID: 528080 Other ID: Nephron 2023;147:317–328

DOI: 10.1159/000528080

PubMed ID: 36630927

SO-VID: 186fda37-af30-4484-bc0a-3e2aa38a54e1

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

History

Date received : 16 July 2022

Date accepted : 21 October 2022

Page count

Figures: 2, Tables: 5, Pages: 12

Funding

This study was funded by Novo Nordisk Foundation (Steno Collaborative Grant, Grant No. NNF17OC0027944). The funder was not involved in the design of the study; the collection, analysis, and interpretation of data; and writing the report; and did not impose any restrictions regarding the publication of the report.

Comments

Comment on this article

scite_

Cited by 1

Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis
Authors: Elina En Li Cho, Chong Zhe Ang, Jingxuan Quek …

See all cited by

Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease

Read this article at

Abstract

Related collections

Karger: Neurology and Neuroscience

Most cited references 53

Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range

Author and article information

Journal

Affiliations

Author information

Article

History

Page count

Funding

Categories

Comments

Comment on this article

Similar content 560

Cited by 1